Inspire Medical (INSP) Q1 2026 earnings review
Growth Story Broken by Coding Crisis
Inspire Medical's multi-year high-growth narrative hit a wall in Q1 2026. Revenue decelerated sharply to just 1.6% YoY growth ($204.6M), missing expectations and forcing management to slash full-year guidance into negative territory. The root cause is a reimbursement disaster: the transition to CPT code 64582 with a -52 modifier has crushed physician economics for the Inspire V procedure, while the WISeR program implementation further disrupted Medicare volumes. Despite a bright spot in gross margins (up 180 bps to 86.5%), the loss of operating leverage is severe, triggering a massive downward revision in full-year earnings expectations.
🐂 Bull Case
The Inspire V system's simpler manufacturing profile is structural. Gross margin expanded 180 bps to 86.5% YoY. If volume returns, the profitability profile of the business will be significantly stronger than in previous years.
Operating cash flow reversed from a $6.7M burn in 25Q1 to a positive $12.8M in 26Q1, driven by disciplined payables and receivables management, proving the company can generate cash even during a growth crisis.
🐻 Bear Case
Just one quarter ago, management guided for 4-10% FY26 revenue growth. They are now guiding for a 4-10% revenue decline, indicating that the coding and reimbursement headwinds are far worse and more permanent than initially telegraphed.
The requirement to use the -52 modifier on the CPT code functionally reduces physician reimbursement by up to 50%. Until a new Category I code is secured (potentially not until 2028), incentivizing private practice surgeons will remain an uphill battle.
⚖️ Verdict: 🔴🔴
Highly Bearish. The company is actively losing its growth momentum. A 1.6% quarterly growth rate and guidance for negative annual growth mark a violent break from the company's historical 50% 5-year CAGR, completely altering the investment thesis until reimbursement is fixed.
Key Themes
Reimbursement Crisis Halts Growth
The primary headwind is the coding transition for the Inspire V system. The previously used CPT code was retired for Medicare, forcing the use of code 64582 with a -52 modifier (indicating a reduced service). This change significantly cuts physician reimbursement. The immediate impact is a devastating deceleration: revenue grew only 1.6% YoY, down from 12% last quarter. Management expects these headwinds to persist through the entirety of 2026.
WISeR Program Disruption (Macro/Regulatory)
Adding to the company's woes is the implementation of the Wasteful and Inappropriate Service Reduction (WISeR) program by Medicare. This prior authorization pilot program created immediate friction in the patient funnel, causing procedure delays and denials. This regulatory macro headwind compound the CPT coding disaster.
Contradictory Narrative on Guidance Feasibility
In 25Q4, management projected confidence that despite the known coding issues, they could achieve 4-10% growth in 2026, leaning on academic centers and Inspire V's clinical superiority. The 26Q1 results shatter this narrative: growth completely stalled, and guidance reversed to a 4-10% contraction. The data suggests management severely underestimated the elasticity of surgeon demand when faced with a 10-50% fee cut.
Inspire V Gross Margin Expansion
The transition to the Inspire V system is providing stable and accelerating margin benefits at the product level. Because Inspire V eliminates the pressure-sensing lead, it is cheaper to manufacture. This drove gross margin up 180 basis points YoY to 86.5%. If the top-line ever recovers, this structural margin improvement will drive heavy profitability.
Working Capital Efficiency Preserves Cash
Despite plunging into a net loss, the company generated $12.8M in operating cash flow, reversing from a $6.7M cash burn a year ago. This was driven primarily by better management of receivables and payables, proving that the balance sheet and cash generation can remain stable during this operational crisis.
Technological Innovation: SleepSync and Inspire 6
To combat the current friction, the company relies heavily on its digital health platform, SleepSync, to streamline prior authorizations. Furthermore, the R&D pipeline is focused on the future Inspire 6 neurostimulator, which aims to incorporate sleep detection and auto-activation, further removing friction from patient compliance.
Other KPIs
Decelerating. OpEx grew only 3.4% YoY. Management is actively applying cost controls, cutting R&D expenses to offset higher legal fees and marketing spend. However, this marginal cost-cutting was vastly insufficient to preserve operating leverage against the stalled revenue.
A severe anomaly. The tax rate exploded due to shortfalls related to stock-based compensation, driven by the decline in the company's stock price at award vesting compared to the grant-date fair value. This uniquely punished the bottom line, driving a net loss of $11.3M.
Guidance
Reversing. Management completely capitulated on their prior $950M-$1.0B guide. The new midpoint ($850M) implies a 7% YoY decline. Because Q1 still grew 1.6%, this implies the company expects heavy revenue contraction across the remaining three quarters of 2026.
Decelerating. Lowered from the previous expectation of 6% to 8%. The massive drop in anticipated procedure volume will deleverage the fixed costs of their sales force and marketing campaigns.
Decelerating sharply. Slashed from the previously guided $1.85 to $2.35. The combination of lower top-line volume and the stock-based compensation tax headwinds severely impair the earnings profile for the year.
Key Questions
Disaggregating the Volume Decline
How much of the Q1 procedure volume miss was specifically due to private practice physicians refusing the economics of the -52 modifier versus outright denials from the WISeR pilot program?
Sequential Contraction
Your new guidance implies negative growth for the rest of the year. Do you expect sequential revenue declines in Q2 and Q3, and what are the specific triggers you need to see to establish a bottom?
Interim Solutions
You noted that a new Category I CPT code might not be effective until 2028. What interim contracting or pricing levers can you pull over the next 18 months to incentivize surgeons and stop the volume bleed?